These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 35790500)

  • 1. A retrospective study of the efficacy and safety of naldemedine for opioid-induced constipation in thoracic cancer patients.
    Imai H; Fujita Y; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Sandoh M; Takei S; Arai K; Nishiba H; Mogi J; Kaira K; Minato K
    Thorac Cancer; 2022 Aug; 13(16):2301-2308. PubMed ID: 35790500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Naldemedine Administration for Opioid-Induced Constipation in Cancer Patients with Poor Performance Status.
    Fujita Y; Imai H; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Sandoh M; Takei S; Arai K; Nishiba H; Mogi J; Koizuka S; Saito T; Obayashi K; Kaira K; Minato K
    J Palliat Med; 2023 Apr; 26(4):548-553. PubMed ID: 36971576
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of naldemedine treatment for opioid-induced constipation in gastrointestinal cancer: a retrospective analysis.
    Nishiba H; Imai H; Fujita Y; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Ito M; Takei S; Matsuura M; Mogi J; Obayashi K; Minato K
    Ann Palliat Med; 2023 Jul; 12(4):697-707. PubMed ID: 37081703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Retrospective Study of the Efficacy and Safety of Naldemedine for Treatment of Opioid-Induced Constipation in Patients with Hepatobiliary Pancreatic Cancer.
    Kamiya T; Imai H; Fujita Y; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Sandoh M; Takei S; Arai K; Nishiba H; Mogi J; Koizuka S; Saito T; Obayashi K; Kaira K; Minato K
    Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984494
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of naldemedine for opioid-induced constipation in older patients with cancer: a retrospective study.
    Imai H; Fujita Y; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Sandoh M; Takei S; Arai K; Nishiba H; Mogi J; Koizuka S; Saito T; Obayashi K; Kaira K; Minato K
    Eur J Gastroenterol Hepatol; 2024 May; 36(5):571-577. PubMed ID: 38477855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials.
    Hale M; Wild J; Reddy J; Yamada T; Arjona Ferreira JC
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):555-564. PubMed ID: 28576452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer.
    Katakami N; Oda K; Tauchi K; Nakata K; Shinozaki K; Yokota T; Suzuki Y; Narabayashi M; Boku N
    J Clin Oncol; 2017 Jun; 35(17):1921-1928. PubMed ID: 28445097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Naldemedine for Opioid-Induced Constipation in Children.
    Miura R; Utano T; Miura Y; Chiba K; Hasegawa A; Takafuji Y; Takahashi H; Tanzawa A; Iwahashi K; Yamatani A; Yotani N
    J Palliat Med; 2024 Oct; 27(10):1354-1358. PubMed ID: 39122251
    [No Abstract]   [Full Text] [Related]  

  • 9. Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysis.
    Kanbayashi Y; Shimizu M; Ishizuka Y; Sawa S; Yabe K; Uchida M
    PLoS One; 2022; 17(12):e0278823. PubMed ID: 36490241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention and management of diarrhea associated with naldemedine among patients receiving opioids: a retrospective cohort study.
    Takagi Y; Osawa G; Kato Y; Ikezawa E; Kobayashi C; Aruga E
    BMC Gastroenterol; 2020 Jan; 20(1):25. PubMed ID: 32005157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Patient Characteristics and Treatment Patterns of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Cancer: A Multicenter Retrospective Chart Review Study.
    Hiruta E; Fujita Y; Imai H; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Ito M; Takei S; Matsuura M; Nishiba H; Mogi J; Kotake M; Koizuka S; Minato K
    Medicina (Kaunas); 2021 Nov; 57(11):. PubMed ID: 34833451
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy of naldemedine for the treatment of opioid-induced constipation: A meta-analysis.
    Esmadi M; Ahmad D; Hewlett A
    J Gastrointestin Liver Dis; 2019 Mar; 28(1):41-46. PubMed ID: 30851171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety and effectiveness of naldemedine for opioid-induced constipation in patients with advanced cancer in real-world palliative care settings: a multicenter prospective observational study.
    Shimizu M; Maeda I; Kessoku T; Ishiki H; Matsuura T; Hiratsuka Y; Matsuda Y; Hasegawa T; Imai K; Oyamada S; Satomi E;
    Support Care Cancer; 2024 Jul; 32(8):504. PubMed ID: 38985364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer.
    Katakami N; Harada T; Murata T; Shinozaki K; Tsutsumi M; Yokota T; Arai M; Tada Y; Narabayashi M; Boku N
    J Clin Oncol; 2017 Dec; 35(34):3859-3866. PubMed ID: 28968171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripherally-active mu-opioid receptor antagonists for constipation in critically ill patients receiving opioids: A case-series and a systematic review and meta-analysis of the literature.
    Umbrello M; Venco R; Palandri C; Racagni M; Muttini S
    Neurogastroenterol Motil; 2023 Dec; 35(12):e14694. PubMed ID: 37869768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A meta-analysis of naldemedine for the treatment of opioid-induced constipation.
    Song X; Wang D; Qu X; Dong N; Teng S
    Expert Rev Clin Pharmacol; 2019 Feb; 12(2):121-128. PubMed ID: 30652502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients ≥ 65 Years of Age.
    Wild J; Webster L; Yamada T; Hale M
    Drugs Aging; 2020 Apr; 37(4):271-279. PubMed ID: 32086791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain.
    Webster LR; Yamada T; Arjona Ferreira JC
    Pain Med; 2017 Dec; 18(12):2350-2360. PubMed ID: 28371937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study.
    Webster LR; Nalamachu S; Morlion B; Reddy J; Baba Y; Yamada T; Arjona Ferreira JC
    Pain; 2018 May; 159(5):987-994. PubMed ID: 29419653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-marketing surveillance of the safety and effectiveness of naldemedine in the management of opioid-induced constipation in patients with cancer pain in Japan.
    Takata K; Nakazawa M; Honda K; Hashimoto S
    Support Care Cancer; 2022 May; 30(5):3943-3954. PubMed ID: 35044484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.